GHRP-2

Source-reported examples · not treatment recommendations

Amount

100–300 micrograms per day in the main example

Frequency

Once daily

Cycle / observation period

8–12 weeks; source also mentions 16 weeks

Route / research model

Subcutaneous

Titration & progression

A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.

Compare vial strengths here. A different vial size changes the available material, not the biological dose.

Diluent & formulation

Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.

Read the reconstitution guide →

Selected observations from the cited research. Each finding retains its study population, formulation and limitations.

• A double-blind study reported in 2014 assigned 126 prepubertal children with growth hormone deficiency to placebo or two intranasal GHRP-2 groups for 48 weeks. Mean height standard-deviation-score changes were 0.07, 0.03 and 0.02, respectively, with no significant between-group difference. IGF-I also did not show a significant group difference. The treatment did not promote growth in this study. ^[2]
• A 12-month study of ten prepubertal children with GH deficiency evaluated oral GHRP-2. Seven reported increased appetite during the first six months, but the change in BMI standard-deviation score was not statistically significant. ^[3]
• FDA identifies immunogenicity and impurity concerns for injectable and nasal GHRP-2. It also notes reports of increased insulin requirements, infection, pancreatitis and deaths among critically ill study participants, while explicitly stating that causality has not been established. ^[7]

Read the complete research profile →

No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.

Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.

Bibliography checked September 22, 2026: 45 entries mapped from 2 source pages. Medical and supporting references are retained below; supplier entries are excluded.

1. Original GHRP-2 appetite study
2. Original full pediatric trial
3. Original pediatric appetite and weight study
4. Original pediatric diagnostic study
5. Original comparative endocrine study
6. Original GHRH/GHRP-2 study
7. FDA safety discussion
8. Domest Anim EndocrinolFurther reading · Listed in reference bibliography.
9. J Clin Endocrinol MetabFurther reading · Listed in reference bibliography.
10. Eur J EndocrinolFurther reading · Listed in reference bibliography.
11. EndocrineFurther reading · Listed in reference bibliography.
12. Am J Men’s HealthFurther reading · Listed in reference bibliography.
13. Sex Med Rev (PMC)Further reading · Listed in reference bibliography.
14. Medicine LibreTexts (BCcampus)Further reading · Listed in reference bibliography.
15. NurseslabsFurther reading · Listed in reference bibliography.
16. JAPIC, GHRP Kaken 100 Official Package Insert - Official pralmorelin identity, 100 mcg presentation, normal-saline preparation, slow IV diagnostic use, and immediate-use handling.Further reading · Listed in reference bibliography.
17. PMDA, Pralmorelin Official Product Record - Current official Japanese product record for the named pralmorelin diagnostic presentation.Further reading · Listed in reference bibliography.
18. Pralmorelin (GHRP-2) — Wikipedia — Overview of GHRP-2 mechanism, ghrelin receptor agonism, and physiological effectsFurther reading · Listed in reference bibliography.
19. PubMed — Growth hormone response to GHRP-2 (PMC3297037) — Pituitary and hypothalamic mechanisms of GH release stimulationFurther reading · Listed in reference bibliography.
20. Pihoker C. et al. (1995) — J Clin Endocrinol Metab — Diagnostic studies with IV and intranasal GHRP-2 in children of short statureFurther reading · Listed in reference bibliography.
21. Sigalos JT. et al. (2017) — Am J Mens Health (PMC5675260) — GH secretagogue therapy raises IGF-1 levels (~50% increase over 3 months)Further reading · Listed in reference bibliography.
22. Kim KS et al. (2003) — Asian-Australas J Anim Sci — Twice‑daily GHRP-2 effects on IGF-1 and tachyphylaxis patternsFurther reading · Listed in reference bibliography.
23. Usach I. et al. (2019) — Adv Ther (PMC6822791) — Subcutaneous injection of drugs: factors influencing pain and techniqueFurther reading · Listed in reference bibliography.
24. MedlinePlus — Subcutaneous (SQ) Injections — Site selection, angle guidance, and rotation best practicesGeneral guidance · Listed in reference bibliography.
25. OncoLink — How To Give a Subcutaneous Injection — Step‑by‑step technique, pinch method, and disposal guidanceFurther reading · Listed in reference bibliography.
26. NCBI Bookshelf — Best Practices for Injections — Asepsis, preparation, and administration standardsFurther reading · Listed in reference bibliography.
27. Cappola et al., 2004, PMID 15126555 - Seventeen healthy older adults received GHRP-2 by continuous SC infusion at 1 mcg/kg/hour for 30 days.Further reading · Listed in reference bibliography.

Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.